Q: What are the Open Access Journals are available in your Publishing group?
Ans: Please visit the mentioned link www.mathewsopenaccess.com to view the list of Journals that are available with us.
Q: How am I to submit my paper?
The candidate is required to send the paper to the individual email of each journal by visiting the concerned journal home page.
Q: When will my paper be published?
Ans: We publish the paper within 3 days after acceptance of the paper.
Q: How do I become peer-Reviewer to the Journal?
Q: Do Editor have to work continuously?
Ans: No, the editorial office will be helping you whenever required as we understand that you may be busy in other commitments.
Q: Whom do I have to contact at the Editorial office if I have any queries?
Q: What is the eligibility do I need to review a manuscript?
Ans: The reviewers are assigned by the Editors as per the research matching to the topic field of manuscript. Self registered peer reviewers must be having a few published papers in the field of interest they mentioned.
Q: Where do I have to submit the Review comments?
Ans: Please submit your review comments in the mentioned form and send us to respective email ID from which you have had received the Manuscript to review.
Q: Is there any limit to review papers?
Ans: No. You may review as many manuscripts you wish according to manuscript topic match your interest.
Published : 01st November 2019
Authors : Bin Wang1,2, Jianhua Ren3, Peng Zhang4, Dusica Cvetkovic1, Xiaoming Chen1, Lili Chen1, and Chang-Ming Charlie Ma1
Citation : Ma CM. (2019). An In-Vivo Study on Pulsed Low-Dose-Rate Radiotherapy for Prostate Cancer. Mathews J Cancer Sci. 4(2): 21.
Published : 17th June 2019
Authors : Reger R. Mikaeel1,2,3,4 , Timothy J. Price1,3, Eric Smith1,5, Paul A. Drew5, Wendy Uylaki1,6, Mehgan Horsnell1, Joanne P. Young1,2,3
Citation : Mikaeel RR. (2019). Colorectal Cancer in Australian Young Adults. Mathews J Cancer Sci. 4(1): 18
Published : 17th March 2019
Authors : Jiancang Wang*, Feifan Du, Ming Su, Xiting Guo, Haixia Tian, Yanxia Song, Liya shang, Wei Zheng, Xiaoge Yang
Citation : Wang J. (2019). Cytomegalovirus Retinitis in a 4-Year-Old Child with Acute Lymphoblastic Leukemia: Treatment and Prognosis. Mathews J Cancer Sci. 4(1): 17
Published : 30th November 2018
Authors : Yang Yang1,3, Olagoke Zacchaeus Olatunde2 , Jianping Yong1 *, Canzhong Lu1,2*
Citation : Yang Y, Olatunde OZ, Yong J and Lu C. (2018). Progress of Chemical Components and Biological Activities of Lonicera Maackii. Mathews J Cancer Sci. 3(1): 016.
Published : 12th November 2018
Authors : Mahdis Solhjoo1*,Alireza Rastgoo Haghi2,Nasim Golchin3,Negar Golchin4,Roham Shahbazi2
Citation : Solhjoo M, Haghi AR, Golchin N, Golchin N, et al. (2018). Expression of E-cadherin and Ki-67 in Gastric Cancer Patients and Cor- relation with Clinicopathological Factors.Mathews J Cancer Sci. 3(1): 015
Published : 18th September 2018
Author : Jussara Maria Gonçalves1 *
Citation : Gonçalves JM. (2018). Cancer Stem Cells: Current Challenge in Cancer Treatment and Important Prognosis Factor.Mathews J Cancer Sci. 3(1): e001
Published : 26th February 2018
Author : Dennis Stamp1*
Citation : Stamp D. (2018). Suggested Model to Induce Esophageal Cancer and Its Precursor Lesions in the Esophagus of Rats. Mathews J Cancer Sci. 3(1): 014.
Published : 27th April 2017
Author : Daniela Capdepón*
Citation : Capdepón D. (2017). Advances in the Care of Diabetes and Cancer. Mathews J Cancer Sci. 2(1): 013.
Published : 01st March 2017
Authors : Aurelio B. Castrellon*, Steven M. Nguyen, Adriana M. Milillo Naraine, Michel Velez, Luis E. Raez
Citation : Castrellon AB, Nguyen SM, Milillo Naraine AM, Velez M, et al. (2017). Initial Response to Therapy with Fulvestrant and Cyclin-Dependent Kinase 4/6 Inhibitor in a Male with Stage IV Breast Cancer.Mathews J Cancer Sci. 2(1): 012.